The short version of GLP-1 receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
One of the SERRS was a "targeted nanoprobe functionalized with an anti-folate-receptor antibody (αFR-Ab) via a PEG-maleimide-succinimide and using the infrared dye IR780 as the Raman reporter, henceforth referred to as αFR-NP, and a nontargeted probe (nt-NP) coated with PEG5000-maleimide and featuring the IR140 infrared dye as the Raman reporter." These two different mixtures were injected into tumor bearing mice and healthy controlled mice. The mice were imaged with Bioluminescence (BLI) signal that produces light energy within an organism's body. They were also scanned with the Raman microscope in order to be able to see the correlation between the TAS3RS and the BLI map. TAS3RS did not show anything in the healthy mice, but was able to locate the tumor lesions in the infected mice and also able to create a TAS3RS map that could be used as guidance during surgery. TAS3RS shows to be promising in being able to combat ovarian and peritoneal cancer as it allows early detection with high accuracy. This technique can be administered locally, which is an advantage as it does not have to enter the bloodstream and therefore bypassing the toxicity concerns circulating nanoprobes. This technique is also more photostable than fluorochromes because SERRS nanoparticles cannot form from biomolecules and therefore there would not be any false positives in TAS3RS as there is in fluorescence imaging.
Allen (born 1960), American chemist who works on interfacial phenomena Adah Almutairi (born 1976), American chemist known for nanomedicine and nanotechnology Sidney Altman (1939–2022), Canadian-American biologist known for catalytic RNA, 1989 Nobel Prize in Chemistry Faiza Al-Kharafi (born 1946), Kuwaiti chemist, academic and the first woman to head a major university in the Middle East Lisa Alvarez-Cohen (PhD 1991), American chemist concerned with microbial degradation of environmental contaminants
== Use and effects == According to Albert Hofmann and colleagues, iso-LSD is inactive as a psychedelic in humans at doses of up to 500 μg, which is up to 25 times the minimum given doses of LSD (i.e., 20–50 μg). In other sources, iso-LSD was also stated as being inactive at doses of up to 50 μg/kg (3.5 mg for a 70-kg person), whereas LSD is active at a dose of 1 μg/kg (70 μg for a 70-kg person). Hence, iso-LSD is inactive in humans at doses of up to 50 times those of a common psychedelic dose of LSD and at doses of up to 175 times the minimum dose of LSD. Alexander Shulgin has additionally reported that iso-LSD was inactive at a dose of 4 mg orally. The related drug isoergine is known to be active in terms of psychoactive and hallucinogenic effects at doses of 2 to 5 mg orally.
== FSH analogues == Corifollitropin alfa Merck received approval on February 15, 2010, from the European Commission for ELONVA (corifollitropin alfa) a long lasting single injection fusion protein lacking LH activity. Only one injection is required for the first seven days, replacing the first seven daily injections of conventional FSH. Initial results demonstrates similar pregnancy rates as daily recombinant FSH injections.
Congenital myopathy is a very broad term for any muscle disorder present at birth. This defect primarily affects skeletal muscle fibres and causes muscular weakness and/or hypotonia. Congenital myopathies account for one of the top neuromuscular disorders in the world today, comprising approximately 6 in 100,000 live births every year. As a whole, congenital myopathies can be broadly classified as follows:
Sources: en.wikipedia.org
Since its founding, the EU has operated among an increasing plurality of member state and globalising legal systems. This has meant both the European Court of Justice and the supreme courts of the states have had to develop principles to resolve conflicts of laws between different systems. Within the EU itself, the Court of Justice's view is that if Union law conflicts with a provision of State law, then Union law has primacy. In the first major case in 1964, Costa v ENEL, a Milanese lawyer, and former shareholder of an energy company, named Mr Costa refused to pay his electricity bill to Enel, as a protest against the Nationalization of the Italian energy corporations. He claimed the Italian nationalisation law conflicted with the Treaty of Rome, and requested a reference be made to both the Italian Constitutional Court and the Court of Justice under TFEU article 267. The Italian Constitutional Court gave an opinion that because the nationalisation law was from 1962, and the treaty was in force from 1958, Costa had no claim. By contrast, the Court of Justice held that ultimately the Treaty of Rome in no way prevented energy nationalisation, and in any case under the Treaty provisions only the commission could have brought a claim, not Mr Costa. However, in principle, Mr Costa was entitled to plead that the Treaty conflicted with national law, and the court would have a duty to consider his claim to make a reference if there would be no appeal against its decision.
Female spotted hyenas exposed to larger doses of androgen have significantly damaged ovaries, making it difficult to conceive. After giving birth, the pseudo-penis is stretched and loses much of its original aspects; it becomes a slack-walled and reduced prepuce with an enlarged orifice with split lips. Approximately 15% of the females die during their first time giving birth, and over 60% of their species' firstborn young die. A 2006 Baskin et al. study concluded, "The basic anatomical structures of the corporeal bodies in both sexes of humans and spotted hyenas were similar. As in humans, the dorsal nerve distribution was unique in being devoid of nerves at the 12 o'clock position in the penis and clitoris of the spotted hyena" and that "[d]orsal nerves of the penis/clitoris in humans and male spotted hyenas tracked along both sides of the corporeal body to the corpus spongiosum at the 5 and 7 o'clock positions. The dorsal nerves penetrated the corporeal body and distally the glans in the hyena", and in female hyenas, "the dorsal nerves fanned out laterally on the clitoral body. Glans morphology was different in appearance in both sexes, being wide and blunt in the female and tapered in the male".
Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. Cobimetinib is a MEK inhibitor. Cobimetinib is marketed by Genentech. The most common side effects include diarrhea, rash, nausea (feeling sick), vomiting, pyrexia (fever), photosensitivity (light sensitivity) reaction, abnormal results for certain liver function tests (increased levels of alanine aminotransferase, aspartate aminotransferase) and abnormal results for an enzyme related to muscle breakdown (creatine phosphokinase). Cobimetinib was approved for medical use in the United States in November 2015.
Helium is the second least reactive noble gas after neon, and thus the second least reactive of all elements. It is chemically inert and monatomic in all standard conditions. Because of helium's relatively low molar (atomic) mass, its thermal conductivity, specific heat, and sound speed in the gas phase are all greater than any other gas except hydrogen. For these reasons and the small size of helium monatomic molecules, helium diffuses through solids at a rate three times that of air and around 65% that of hydrogen. Helium is the least water-soluble monatomic gas, and one of the least water-soluble of any gas (CF4, SF6, and C4F8 have lower mole fraction solubilities: 0.3802, 0.4394, and 0.2372 x2/10−5, respectively, versus helium's 0.70797 x2/10−5), and helium's index of refraction is closer to unity than that of any other gas. Helium has a negative Joule–Thomson coefficient at normal ambient temperatures, meaning it heats up when allowed to freely expand. Only below its Joule–Thomson inversion temperature (of about 32 to 50 K (−241.2 to −223.2 °C; −402.1 to −369.7 °F) at one atm (0.10 MPa)) does it cool upon free expansion. Once precooled below this temperature, helium can be liquefied through expansion cooling. Most extraterrestrial helium is plasma in stars, with properties quite different from those of atomic helium. In a plasma, helium's electrons are not bound to its nucleus, resulting in very high electrical conductivity, even when the gas is only partially ionized. The charged particles are highly influenced by magnetic and electric fields.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Reverse-phase liquid chromatography and mass spectrometry are the most common techniques. Chromatography assesses purity, while mass spectrometry confirms molecular identity. Additional methods may be applied when higher confidence is required.